These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 2532813)

  • 1. Immunogenicity of a new type of yeast-derived hepatitis B vaccine consisting of M (pre-S2 + S) protein particles.
    Hazama M; Takaoki M; Ohfune K; Hinuma S; Fujisawa Y
    Vaccine; 1989 Dec; 7(6):567-73. PubMed ID: 2532813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective efficacy of a novel hepatitis B vaccine consisting of M (pre-S2 + S) protein particles (a third generation vaccine).
    Fujisawa Y; Kuroda S; Van Eerd PM; Schellekens H; Kakinuma A
    Vaccine; 1990 Jun; 8(3):192-8. PubMed ID: 2363298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of protection level of anti-pre-S2 antibodies in humans immunized with a novel hepatitis B vaccine consisting of M (pre-S2 + S) protein particles (a third generation vaccine).
    Kuroda S; Fujisawa Y; Iino S; Akahane Y; Suzuki H
    Vaccine; 1991 Mar; 9(3):163-9. PubMed ID: 1828318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved immunogenicity in mice of a mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens as compared with conventional yeast-derived vaccines.
    Shouval D; Ilan Y; Adler R; Deepen R; Panet A; Even-Chen Z; Gorecki M; Gerlich WH
    Vaccine; 1994 Nov; 12(15):1453-9. PubMed ID: 7533967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of a recombinant yeast-derived pre-S2 + S-containing hepatitis B vaccine (TGP-943): phase 1, 2 and 3 clinical testing.
    Suzuki H; Iino S; Shiraki K; Akahane Y; Okamoto H; Domoto K; Mishiro S
    Vaccine; 1994 Sep; 12(12):1090-6. PubMed ID: 7998418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Immunogenicity and harmlessness in the newborn of a vaccine (GenHevac B) containing the antigens S and pre-S2].
    Tron F; Soulié JC; Goudeau A; Devillier P; Saliou P
    Bull Soc Pathol Exot; 1991; 84(5 Pt 5):901-5. PubMed ID: 1840243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of two differently glycosylated molecular species of yeast-derived hepatitis B vaccine carrying the pre-S2 region.
    Kobayashi M; Asano T; Ohfune K; Kato K
    J Biotechnol; 1992 Nov; 26(2-3):155-62. PubMed ID: 1369148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and safety in newborns of a new recombinant hepatitis B vaccine containing the S and pre-S2 antigens.
    Soulié JC; Devillier P; Santarelli J; Goudeau A; Vermeulen P; Guellier M; Saliou P; Hillion AM; Tron F; Huchet J
    Vaccine; 1991 Aug; 9(8):545-8. PubMed ID: 1837646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T-cell and antibody response characterisation of a new recombinant pre-S1, pre-S2 and SHBs antigen-containing hepatitis B vaccine; demonstration of superior anti-SHBs antibody induction in responder mice.
    Jones CD; Page M; Bacon A; Cahill E; Bentley M; Chatfield SN
    Vaccine; 1999 Jun; 17(20-21):2528-37. PubMed ID: 10418899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in neonates.
    Yerushalmi B; Raz R; Blondheim O; Shumov E; Koren R; Dagan R
    Pediatr Infect Dis J; 1997 Jun; 16(6):587-92. PubMed ID: 9194109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of a 'pre-S2 plus S' hepatitis B vaccine in healthy adults.
    Katkov WN; Watkins E; DeMelia HC; Dienstag JL
    J Viral Hepat; 1994; 1(1):79-83. PubMed ID: 8790563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-pre-S2 antibodies in natural hepatitis B virus infection and after immunization.
    Coursaget P; Adamowicz P; Bourdil C; Yvonnet B; Buisson Y; Barrès JL; Saliou P; Chiron JP; Mar ID
    Vaccine; 1988 Aug; 6(4):357-61. PubMed ID: 2973189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative safety and immunogenicity of yeast recombinant hepatitis B vaccines containing S and pre-S2 + S antigens.
    Miskovsky E; Gershman K; Clements ML; Cupps T; Calandra G; Hesley T; Ioli V; Ellis R; Kniskern P; Miller W
    Vaccine; 1991 May; 9(5):346-50. PubMed ID: 1872019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the T- and B-cell immune response to a new recombinant pre-S1, pre-S2 and SHBs antigen containing hepatitis B vaccine (Hepagene); evidence for superior anti-SHBs antibody induction in responder mice.
    Jones CD; Page M; Bacon A; Cahill E; Bentley M; Chatfield SN
    J Viral Hepat; 1998 Nov; 5 Suppl 2():5-8. PubMed ID: 9857353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of a new mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in adults.
    Raz R; Koren R; Bass D
    Isr Med Assoc J; 2001 May; 3(5):328-32. PubMed ID: 11411195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced immune response to hepatitis B vaccination through immunization with a Pre-S1/Pre-S2/S vaccine.
    Shouval D; Roggendorf H; Roggendorf M
    Med Microbiol Immunol; 2015 Feb; 204(1):57-68. PubMed ID: 25557605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis B vaccination in diabetic patients. Randomized trial comparing recombinant vaccines containing and not containing pre-S2 antigen.
    Douvin C; Simon D; Charles MA; Deforges L; Bierling P; Lehner V; Budkowska A; Dhumeaux D
    Diabetes Care; 1997 Feb; 20(2):148-51. PubMed ID: 9118762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antibody responses in human being to pre-S2 and related hepatitis B virus-envelope antigens in vivo and in vitro].
    Ogata M; Ishikawa H; Kato Y; Honta S; Yoshida H; Yasuda H; Ohto H; Watanabe N
    Rinsho Byori; 1991 Jan; 39(1):3-13. PubMed ID: 1826138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-pre-S2 antibody response in subjects vaccinated against hepatitis B and in naturally immunized subjects.
    Lavanchy D; Fritzell B; Geudelin B; Peitrequin R; Frei PC
    Res Virol; 1991; 142(5):363-71. PubMed ID: 1837611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid seroprotection against hepatitis B following the first dose of a Pre-S1/Pre-S2/S vaccine.
    Shapira MY; Zeira E; Adler R; Shouval D
    J Hepatol; 2001 Jan; 34(1):123-7. PubMed ID: 11211888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.